Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells

Overview of attention for article published in Carcinogenesis, January 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

patent: 6 patents

facebook: 1 Facebook page

Readers on

mendeley: 80 Mendeley

So far, Altmetric has seen 6 patents that reference this research output.

Combinations of LSD1 inhibitors for use in the treatment of solid tumors

Grant US-12564559-B2

United States of America

03 Mar 2026

Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors

Grant US-12479797-B2

United States of America

25 Nov 2025

DUAL LSD1/HDAC INHIBITORS

Application WO-2023170715-A1

World Intellectual Property Organisation (WIPO)

14 Sep 2023

Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors

Grant US-11352322-B2

United States of America

07 Jun 2022

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 2 additional patents.